205 related articles for article (PubMed ID: 37041476)
1. SLC27A2 mediates FAO in colorectal cancer through nongenic crosstalk regulation of the PPARs pathway.
Shang K; Ma N; Che J; Li H; Hu J; Sun H; Cao B
BMC Cancer; 2023 Apr; 23(1):335. PubMed ID: 37041476
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of PGC-1α increases peroxisomal activity and mitochondrial fatty acid oxidation in human primary myotubes.
Huang TY; Zheng D; Houmard JA; Brault JJ; Hickner RC; Cortright RN
Am J Physiol Endocrinol Metab; 2017 Apr; 312(4):E253-E263. PubMed ID: 28073778
[TBL] [Abstract][Full Text] [Related]
3. Upregulated SLC27A2/FATP2 in differentiated thyroid carcinoma promotes tumor proliferation and migration.
Feng K; Ma R; Li H; Yin K; Du G; Chen X; Liu Z; Yin D
J Clin Lab Anal; 2022 Jan; 36(1):e24148. PubMed ID: 34854499
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism.
Latruffe N; Vamecq J
Biochimie; 1997; 79(2-3):81-94. PubMed ID: 9209701
[TBL] [Abstract][Full Text] [Related]
5. Yarrowia lipolytica AAL genes are involved in peroxisomal fatty acid activation.
Dulermo R; Gamboa-Meléndez H; Ledesma-Amaro R; Thevenieau F; Nicaud JM
Biochim Biophys Acta; 2016 Jul; 1861(7):555-65. PubMed ID: 27067366
[TBL] [Abstract][Full Text] [Related]
6. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR).
Dreyer C; Keller H; Mahfoudi A; Laudet V; Krey G; Wahli W
Biol Cell; 1993; 77(1):67-76. PubMed ID: 8390886
[TBL] [Abstract][Full Text] [Related]
7. Acyl-CoA synthetase long-chain 3-mediated fatty acid oxidation is required for TGFβ1-induced epithelial-mesenchymal transition and metastasis of colorectal carcinoma.
Quan J; Cheng C; Tan Y; Jiang N; Liao C; Liao W; Cao Y; Luo X
Int J Biol Sci; 2022; 18(6):2484-2496. PubMed ID: 35414781
[TBL] [Abstract][Full Text] [Related]
8. Increased peroxisomal fatty acid beta-oxidation and enhanced expression of peroxisome proliferator-activated receptor-alpha in diabetic rat liver.
Asayama K; Sandhir R; Sheikh FG; Hayashibe H; Nakane T; Singh I
Mol Cell Biochem; 1999 Apr; 194(1-2):227-34. PubMed ID: 10391144
[TBL] [Abstract][Full Text] [Related]
9. PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism.
Dai W; Xiang W; Han L; Yuan Z; Wang R; Ma Y; Yang Y; Cai S; Xu Y; Mo S; Li Q; Cai G
Cancer Commun (Lond); 2022 Sep; 42(9):848-867. PubMed ID: 35904817
[TBL] [Abstract][Full Text] [Related]
10. Peroxisomes in cardiomyocytes and the peroxisome / peroxisome proliferator-activated receptor-loop.
Colasante C; Chen J; Ahlemeyer B; Baumgart-Vogt E
Thromb Haemost; 2015 Mar; 113(3):452-63. PubMed ID: 25608554
[TBL] [Abstract][Full Text] [Related]
11. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling.
Yoshikawa T; Ide T; Shimano H; Yahagi N; Amemiya-Kudo M; Matsuzaka T; Yatoh S; Kitamine T; Okazaki H; Tamura Y; Sekiya M; Takahashi A; Hasty AH; Sato R; Sone H; Osuga J; Ishibashi S; Yamada N
Mol Endocrinol; 2003 Jul; 17(7):1240-54. PubMed ID: 12730331
[TBL] [Abstract][Full Text] [Related]
12. Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling.
Su J; Wu S; Tang W; Qian H; Zhou H; Guo T
Mol Carcinog; 2016 Nov; 55(11):1822-1832. PubMed ID: 26513225
[TBL] [Abstract][Full Text] [Related]
13. SLC27A2 is a potential immune biomarker for hematological tumors and significantly regulates the cell cycle progression of diffuse large B-cell lymphoma.
Wang Y; Chen X; Li Y; Zhang Z; Xia L; Jiang J; Chai Y; Wang Z; Wan Y; Li T; Jin F; Li H
BMC Med Genomics; 2024 Apr; 17(1):105. PubMed ID: 38664735
[TBL] [Abstract][Full Text] [Related]
14. Transactivation by PPAR/RXR heterodimers in yeast is potentiated by exogenous fatty acid via a pathway requiring intact peroxisomes.
Marcus SL; Miyata KS; Rachubinski RA; Capone JP
Gene Expr; 1995; 4(4-5):227-39. PubMed ID: 7787415
[TBL] [Abstract][Full Text] [Related]
15. PPAR: a mediator of peroxisome proliferator action.
Green S
Mutat Res; 1995 Dec; 333(1-2):101-9. PubMed ID: 8538617
[TBL] [Abstract][Full Text] [Related]
16. The Role of PPARs in Breast Cancer.
Zhao B; Xin Z; Ren P; Wu H
Cells; 2022 Dec; 12(1):. PubMed ID: 36611922
[TBL] [Abstract][Full Text] [Related]
17. Peroxisomes can oxidize medium- and long-chain fatty acids through a pathway involving ABCD3 and HSD17B4.
Violante S; Achetib N; van Roermund CWT; Hagen J; Dodatko T; Vaz FM; Waterham HR; Chen H; Baes M; Yu C; Argmann CA; Houten SM
FASEB J; 2019 Mar; 33(3):4355-4364. PubMed ID: 30540494
[TBL] [Abstract][Full Text] [Related]
18. SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer.
Chen FD; Chen HH; Ke SC; Zheng LR; Zheng XY
Neoplasma; 2018 Nov; 65(6):915-924. PubMed ID: 30334452
[TBL] [Abstract][Full Text] [Related]
19. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression.
Schoonjans K; Staels B; Auwerx J
J Lipid Res; 1996 May; 37(5):907-25. PubMed ID: 8725145
[TBL] [Abstract][Full Text] [Related]
20. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
Alemán G; Torres N; Tovar AR
Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
